{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:35:10Z","timestamp":1782837310840,"version":"3.54.5"},"reference-count":44,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>In Belgium, linezolid is indicated for pneumonia and skin and soft tissue infections, but is more broadly used, due to its oral bioavailability and activity against multiresistant organisms. This could increase the risk of adverse drug reactions (ADR), notably hematological disorders (anemia, thrombocytopenia), neuropathy, or lactic acidosis. We analyzed linezolid clinical use in relationship with occurrence of ADR in Belgian hospitals and highlighted risk factors associated with the development of thrombocytopenia. A retrospective analysis of electronic medical records and laboratory tests of adult patients treated with linezolid in four Belgian hospitals in 2016 allowed the collection of ADR for 248 linezolid treatments. Only 19.7% of indications were in-label. ADR included 43 thrombocytopenia, 17 anemia, 4 neuropathies, and 4 increases in lactatemia. In a multi-variate analysis, risk factors of thrombocytopenia were a treatment duration &gt; 10 days, a glomerular filtration rate &lt; 60 mL\/min, and a Charlson index \u2265 4. Off-label use of linezolid is frequent in Belgium, and ADR more frequent than reported in the summary of product characteristics, but not statistically associated with any indication. This high prevalence of ADR could be related to a high proportion of patients presenting risk factors in our population, highlighting the importance of detecting them prospectively.<\/jats:p>","DOI":"10.3390\/antibiotics10050530","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T11:06:01Z","timestamp":1620212761000},"page":"530","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers"],"prefix":"10.3390","volume":"10","author":[{"given":"H\u00e9l\u00e8ne","family":"Thirot","sequence":"first","affiliation":[{"name":"Pharmacologie Cellulaire et Mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"},{"name":"Clinical Pharmacy, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0142-8741","authenticated-orcid":false,"given":"Caroline","family":"Briquet","sequence":"additional","affiliation":[{"name":"Groupe de Gestion de L\u2019antibioth\u00e9rapie, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Frippiat","sequence":"additional","affiliation":[{"name":"Infectiologie, Centre Hospitalier Universitaire de Li\u00e8ge, Universit\u00e9 de Li\u00e8ge, B4000 Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Cliniques Universitaires Erasme, Universit\u00e9 libre de Bruxelles, B1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7812-2196","authenticated-orcid":false,"given":"Xavier","family":"Holemans","sequence":"additional","affiliation":[{"name":"Grand H\u00f4pital de Charleroi, Infectiologie, B6000 Charleroi, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-8093","authenticated-orcid":false,"given":"S\u00e9verine","family":"Henrard","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"},{"name":"Institute of Health and Society (IRSS), Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-3623","authenticated-orcid":false,"given":"Paul M.","family":"Tulkens","sequence":"additional","affiliation":[{"name":"Pharmacologie Cellulaire et Mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Spinewine","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"},{"name":"CHU UCL Namur, Pharmacy Department, Universit\u00e9 Catholique de Louvain, B5530 Yvoir, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-7991","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[{"name":"Pharmacologie Cellulaire et Mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain, B1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1073\/pnas.1613055113","article-title":"Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center","volume":"113","author":"Marks","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","unstructured":"(2021, April 09). Zyvox 600 mg Film-Coated Tablets\u2014Summary of Product Characteristics (SmPC). Available online: https:\/\/www.medicines.org.uk\/emc\/medicine\/9857#gref."},{"key":"ref_3","unstructured":"FDA (2021, April 12). FDA Label Zyvox, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021130s037,021131s030,021132s035lbl.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dkl219","article-title":"Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence","volume":"58","author":"Falagas","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s15010-004-3029-9","article-title":"Linezolid in the treatment of osteomyelitis: Results of compassionate use experience","volume":"32","author":"Rayner","year":"2004","journal-title":"Infection"},{"key":"ref_7","first-page":"61","article-title":"Optic neuropathy associated with linezolid: Systematic review of cases","volume":"43","year":"2019","journal-title":"Farm. Hosp."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/B978-0-444-52902-2.00042-4","article-title":"Drug-induced neuropathies","volume":"115","author":"Manji","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2014.12.009","article-title":"Incidence and risk factors of linezolid-induced lactic acidosis","volume":"31","author":"Im","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e12114","DOI":"10.1097\/MD.0000000000012114","article-title":"The risk factors of linezolid-induced lactic acidosis: A case report and review","volume":"97","author":"Mao","year":"2018","journal-title":"Med. (Baltim.)"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1345\/aph.1R386","article-title":"Clinical relevance of linezolid-associated serotonin toxicity","volume":"47","author":"Woytowish","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/AAC.47.6.1824-1831.2003","article-title":"Worldwide assessment of linezolid\u2019s clinical safety and tolerability: Comparator-controlled phase III studies","volume":"47","author":"Rubinstein","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/jac\/dkg253","article-title":"Safety and tolerability of linezolid","volume":"51","author":"French","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","article-title":"Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients","volume":"36","author":"Hirano","year":"2014","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s15010-014-0674-5","article-title":"Risk factors for linezolid-associated thrombocytopenia in adult patients","volume":"42","author":"Natsumoto","year":"2014","journal-title":"Infection"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2014.01.012","article-title":"Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight","volume":"79","author":"Niwa","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1517\/14656566.8.14.2381","article-title":"Linezolid: Effectiveness and safety for approved and off-label indications","volume":"8","author":"Vardakas","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/QCO.0000000000000142","article-title":"Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?","volume":"28","author":"Dryden","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11096-014-9995-9","article-title":"Antimicrobial stewardship and linezolid","volume":"36","author":"Guillard","year":"2014","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","article-title":"Association of Off-label Drug Use and Adverse Drug Events in an Adult Population","volume":"176","author":"Eguale","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_23","unstructured":"European Medicines Agency (2021, April 14). Reflection Paper on Collecting and Reporting Information on Off-Label Use in Pharmacovigilance. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/reflection-paper-collecting-reporting-information-label-use-pharmacovigilance_en.pdf."},{"key":"ref_24","unstructured":"Dal Pan, G.J. (2021, April 14). Monitoring the Safety of Medicines Used Off-Label. Available online: https:\/\/www.pharmaco-vigilance.eu\/content\/monitoring-safety-medicines-used-label."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10096-017-2960-5","article-title":"Predictive score of haematological toxicity in patients treated with linezolid","volume":"36","author":"Candel","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_26","first-page":"857","article-title":"Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital","volume":"14","year":"2015","journal-title":"Iran J. Pharm. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10096-017-2900-4","article-title":"Assessment of linezolid prescriptions in three French hospitals","volume":"36","author":"Dentan","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.farma.2011.04.001","article-title":"Effectiveness and use of linezolid in hospitalisation wards","volume":"35","author":"Rivas","year":"2011","journal-title":"Farm. Hosp."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1586\/eri.12.137","article-title":"Frequency of the off-label use of antibiotics in clinical practice: A systematic review","volume":"10","author":"Tansarli","year":"2012","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijantimicag.2016.04.010","article-title":"High rates of off-label use in antibiotic prescriptions in a context of dramatic resistance increase: A prospective study in a tertiary hospital","volume":"47","author":"Davido","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of Adverse Events with Antibiotic Use in Hospitalized Patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijantimicag.2015.09.002","article-title":"Linezolid-related adverse events predictive score (LAPS): Usefulness in clinical practice","volume":"46","author":"Buzele","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_37","first-page":"133","article-title":"Real-Life Frequency of New-Onset Thrombocytopenia during Linezolid Treatment","volume":"72","author":"Brown","year":"2019","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/1060028018783498","article-title":"Incidence and Risk Factors for Development of Thrombocytopenia in Patients Treated With Linezolid for 7 Days or Greater","volume":"52","author":"Rabon","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jcpt.12260","article-title":"The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: A retrospective analysis","volume":"40","author":"Ichie","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"g1626","DOI":"10.1136\/bmj.g1626","article-title":"Serotonin syndrome","volume":"348","author":"Buckley","year":"2014","journal-title":"BMJ"},{"key":"ref_44","first-page":"19","article-title":"Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia","volume":"38","author":"Rondina","year":"2010","journal-title":"Hosp. Pract."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/5\/530\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:57:05Z","timestamp":1760162225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/5\/530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["antibiotics10050530"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10050530","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}